Interim Report 2026
Filed with HKEX · Stock code 460 · · 115 pages · English and Chinese
Sihuan Pharmaceutical Holdings Group Ltd. on 6ix
Earlier from Sihuan Pharmaceutical
- Voluntary announcement - insulin aspart 30 injection developed by Sihuan Pharmaceutical achieved equivalent clinical results in efficacy and safety study as originator drug
- Voluntary announcement-entering into strategic cooperation agreement between jilin huisheng biopharmaceutical and porton pharma
- Voluntary announcement - share repurchase
- Voluntary announcement-Sihuan Pharmaceutical obtained drug registration approval in relation to ambroxol hydrochloride injection
- Voluntary announcement proposed share repurchase under the general mandate
Later from Sihuan Pharmaceutical
- Notification Letter and Change Request Form to Registered Shareholder
- Notification Letter and Request Form to Non-registered Holder
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - new specifications of skin booster (brand name: dongyan) of Sihuan Pharmaceutical approved for launch by nmpa
- Voluntary announcement-Sihuan Pharmaceutical completed a strategic investment in canton biologics to enhance the layout of the entire industrial chain of regenerative medical aesthetics
Follow Sihuan Pharmaceutical into a list and get an email when it puts out news.
Follow Sihuan Pharmaceutical